Avara Avlon falls into administration putting 270 Bristol jobs at risk
pharmafile | February 21, 2019 | News story | Manufacturing and Production | AstraZeneca, Avara Avlon, Bristol, CDMO, Jobs, UK, manufacturing
Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk.
The contract development and manufacturing organisation (CDMO) is hoping to sell facilities in Avonmouth a suburb of Bristol, which it bought from AstraZeneca in 2016.
David Rubin, of insolvency partners David Rubin and Partners, who are overseeing the administration process, commented: “Avlon has experienced financial difficulties in recent months as a result of a major contract with a customer coming to an end. The Joint Administrators are now managing the site, whilst they seek a buyer for the business and assets.”
“The main issues here are keeping the site operational and ensuring that all health, safety and environment obligations are complied with.”
“We are working closely with the highly professional and experienced workforce to do everything we can to obtain the best outcome for all stakeholders.”
“We have already secured an agreement with the major customer that gives the business immediate short-term funding and means that we do not immediately have to consider mass redundancies.”
The site had previously been earmarked for closure in 2016, after the expiry of a number of AstraZeneca’s patents.
However the 210 employees were saved from redundancy through the deal with Avara. The deal sw Avara manufacture API’s for AstraZeneca on a contract basis.
Louis Goss
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …